Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Pfizer Considers Acquisition of Cancer Biotech, Medivation

XTALKS VITALS NEWS

Mergers & Acquisitions

Medivation has reportedly not decided whether they will engage in negotiations with Pfizer, who has yet to make a formal bid for the company.

Share this!

May 5, 2016 | by Sarah Massey, M.Sc.

According to a report by Reuters, Pfizer has approached Medivation to discuss a possible takeover deal. The news comes just days after Sanofi’s $9.3 billion bid was rejected by the cancer biotech.

Just one week ago, Sanofi went public with its cash offer for Medivation, valued at $52.50 per share. David Hung, CEO of Medivation, said, “We believe the continued successful execution of our well-defined strategic plan will deliver greater value to Medivation's stockholders than Sanofi's substantially inadequate proposal.”

Medivation has reportedly not decided whether they will engage in negotiations with Pfizer, who has yet to make a formal bid for the company. According to sources, Sanofi will wait until Medivation shows interest in selling before making a new bid.

With interest from Pfizer, Sanofi and AstraZeneca, Medivation may be able to command a higher price, if and when they decide to sell. The company’s lead asset – a prostate cancer drug called Xtandi – generated $1.9 billion in global sales in 2015. Medivation and Astellas divide all US revenue equally, with Medivation earning a royalty on international sales.



For Pfizer, the acquisition could help them boost their patented drug portfolio. Medivation would also be an important oncology buy for the company after the $160 billion merger with Allergan was scrapped.

Earlier this week, Pfizer reported strong earnings for the first quarter of the year. While previously well-performing drugs – such as Viagra and Lipitor – have shown flat or declining revenues, new drugs have helped to drive higher sales.

Interest in Medivation has already helped to increase the company’s stock to over $58 per share. This value is well over Sanofi’s offer, suggesting that other contenders will have to give them a higher valuation before they decide to sell.


Keywords: Cancer, Mergers & Acquisitions, Pfizer


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.